Cancer diagnoses traditionally require invasive or labor-intensive procedures such as tissue biopsies. Researchers at the Ludwig-Maximilians-Universität München (LMU) have now reported on a method ...

The blood-based test by Astrin Biosciences shows high sensitivity and specificity across cancer stages and subtypes, addressing mammography's limitations in dense breast tissue. The test achieved 92.3 ...

Endometrial cancer is one of the most common cancers in Australian women—and one of the hardest to catch. But a new breakthrough in AI cancer detection is pushing accuracy levels to an unprecedented ...

As the diagnostic landscape evolves, several patterns are emerging across both clinical research and market innovation.

Conventional diagnostic tools, such as ultrasound, MRI, PET, CT scans, and scintigraphy, often identify cancer only at later stages. These methods can be expensive, expose patients to radiation, and ...

Cancer ranks as one of the top causes of death worldwide. The National Cancer Institute reported nearly 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2022, with ...

The next breakthrough in cancer screening is emerging from the convergence of artificial intelligence and canine biology. That’s the thesis behind SpotitEarly, a startup that recently launched in the ...

SpotitEarly, a biotech startup that uses AI and dogs to detect cancer using an at-home test, announced its launch into the U.S. market with $20.3 million in funding. The company has received funding ...

Using a single blood sample, multi-cancer early detection (MCED) tests screen for numerous types of cancers, including breast, ovarian, colorectal, pancreatic and prostate cancers. Trials are underway ...

Some claim the new multi-cancer detection tests will “revolutionize” cancer screening. Others fear the “worried well” will succumb to slick marketing and subpar tests and overwhelm both primary care ...